In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa from sub-Saharan Africa: ATLAS Global Surveillance Program 2017–2021

Magiorakos, 2012, Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance, Clin Microbiol Infect, 18, 268, 10.1111/j.1469-0691.2011.03570.x Kadri, 2018, Difficult-to-treat resistance in Gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents, Clin Infect Dis, 67, 1803 Mitang, 2018, Review and mapping of carbapenem-resistant Enterobacteriaceae in Africa: using diverse data to inform surveillance gaps, Int J Antimicrob Agents, 52, 372, 10.1016/j.ijantimicag.2018.05.019 Karlowsky, 2016, Activity of ceftazidime-avibactam against extended-spectrum- and AmpC β-lactamase-producing Enterobacteriaceae collected in the INFORM global surveillance study from 2012 to 2014, Antimicrob Agents Chemother, 60, 2849, 10.1128/AAC.02286-15 Nichols, 2016, In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to ceftazidime-avibactam (INFORM 2012 to 2014), Antimicrob Agents Chemother, 60, 4743, 10.1128/AAC.00220-16 Spiliopoulou, 2020, In vitro activity of ceftazidime/avibactam against isolates of carbapenem-non-susceptible Enterobacteriaceae collected during the INFORM global surveillance programme (2015–2017), J Antimicrob Chemother, 75, 384, 10.1093/jac/dkz456 2018 2022 EUCAST breakpoint tables for interpretation of MICs and zone diameters. Version 12.0, January 2022. http://www.eucast.org/clinical_breakpoints/. Lob, 2018, Antimicrobial resistance and resistance mechanisms of Enterobacteriaceae in ICU and non-ICU wards in Europe and North America: SMART 2011–2013, J Glob Antimicrob Resist, 3, 190, 10.1016/j.jgar.2015.05.005 EUCAST breakpoints in brackets. December 2021. http://www.eucast.org/clinical_breakpoints_and_dosing/breakpoints_in_brackets. Berrazeg, 2015, Mutations in β-lactamase AmpC increase resistance of Pseudomonas aeruginosa isolates to antipseudomonal cephalosporins, Antimicrob Agents Chemother, 59, 6248, 10.1128/AAC.00825-15 Drusano, 2021, Emergence of resistance to ceftazidime-avibactam in a Pseudomonas aeruginosa isolate producing derepressed blaPDC in a hollow-fiber infection model, Antimicrob Agents Chemother, 65, 21, 10.1128/AAC.00124-21 Gaibani, 2022, Resistance to ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam in Gram-negative MDR bacilli: molecular mechanisms and susceptibility testing, Antibiotics (Basel), 11, 628, 10.3390/antibiotics11050628 Lopez-Montesinos, 2022, Suboptimal concentrations of ceftazidime/avibactam (CAZ-AVI) may select for CAZ-AVI resistance in extensively drug-resistant Pseudomonas aeruginosa: in vivo and in vitro evidence, Antibiotics (Basel), 11, 1456, 10.3390/antibiotics11111456 Huh, 2020, Impact of difficult-to-treat resistance in Gram-negative bacteremia on mortality: retrospective analysis of nationwide surveillance data, Clin Infect Dis, 71, e487 Karlowsky, 2021, Clin Infect Dis, 72, 2112, 10.1093/cid/ciaa381 Karlowsky, 2021, In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa from Middle Eastern and African countries: ATLAS global surveillance programme 2015-18, JAC Antimicrob Resist, 3, dlab067, 10.1093/jacamr/dlab067 Giannelli, 2019, Prognostic utility of the new definition of difficult-to-treat resistance among patients with Gram-negative bloodstream infections, Open Forum Infect Dis, 6, ofz505, 10.1093/ofid/ofz505 Allergan, Inc. AVYCAZ® package insert. 2022. https://www.allergan.com/assets/pdf/avycaz_pi. Pfizer Pharmaceuticals. Zavicefta summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/zavicefta-epar-product-information_en.pdf [accessed 24 February 2023]. Tamma, 2021, Clin Infect Dis, 72, e169, 10.1093/cid/ciaa1478 Brink, 2022, Best practices: appropriate use of the new β-lactam/β-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam in South Africa, S Afr J Infect Dis, 37, 453 Khan, 2021, Evaluation of susceptibility testing methods for aztreonam and ceftazidime-avibactam combination therapy on extensively drug-resistant Gram-negative organisms, Antimicrob Agents Chemother, 65, 10.1128/AAC.00846-21